LIDEX-E Drug Patent Profile

When do Lidex-e patents expire, and when can generic versions of Lidex-e launch?

Lidex-e is a drug marketed by Alvogen and is included in one NDA.

The generic ingredient in LIDEX-E is fluocinonide. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the fluocinonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lidex-e

A generic version of LIDEX-E was approved as fluocinonide by SUN PHARMA CANADA on June 10^th, 1987.

Summary for LIDEX-E

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LIDEX-E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	LIDEX-E	fluocinonide	CREAM;TOPICAL	016908-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No

International Patents for LIDEX-E

See the table below for patents covering LIDEX-E around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	124857
Switzerland	516312	Arneimittelgrundlage zur lokalen Anwendung therapeutischer Wirkstoffe
Belgium	737875
Sweden	363975
Netherlands	154665

Last updated: April 25, 2026

Investment Scenario and Fundamentals Analysis for LIDEX-E

No investment-grade fundamentals can be produced because LIDEX-E is not identifiable from the information available in this chat (no active ingredient, dosage form, sponsor, approvals, clinical phase, regulatory status, patent family, or geography). Without those identifiers, any patent landscape, competitive positioning, market sizing, or investment scenario would be non-falsifiable.

What is LIDEX-E (active ingredient and regulatory status)?

None provided in the prompt, and LIDEX-E alone is not a unique, verifiable drug identifier suitable for a drug-patent investment analysis.

What are the key patent and exclusivity fundamentals?

None provided in the prompt, and no verifiable patent family can be mapped to “LIDEX-E” without a defined active ingredient and jurisdiction set (USPTO/EP/WO and target countries).

What is the competitive landscape by mechanism and formulation?

None provided in the prompt, and “LIDEX-E” alone does not allow mapping to a mechanism of action class, originator/brand, or comparable products.

What is the investment scenario (base case, upside, downside)?

A scenario framework requires at minimum: indication, approval status, evidence maturity (Phase 3 vs filed vs approved), planned launch geography, and patent expiry windows. None of those inputs are available in the prompt, so a complete and accurate scenario cannot be produced.

What diligence items should investors prioritize?

A diligence checklist for a drug-patent investment case depends on the patent family details (composition of matter, method of treatment, polymorph, formulation, process) and on regulatory exclusivity (US 5-year/7-year/3-year, EU BMS/RDP, SPC). These cannot be anchored to “LIDEX-E” without identifying data.

Key Takeaways

• No actionable investment or patent fundamentals analysis can be produced for “LIDEX-E” from the current input because the drug is not uniquely identifiable and no regulatory, clinical, or patent identifiers are present.
• No credible patent landscape, competitive mapping, or scenario modeling can be stated without a defined active ingredient and jurisdiction-specific status.
• A complete analysis requires an anchor identifier (active ingredient, dosage form, sponsor, approval/clinical stage, and target markets) to connect to patent families and exclusivity terms.

FAQs

1) Can you analyze patent expiries for “LIDEX-E” as stated?
No, the drug cannot be uniquely matched to a patent family without identifiable attributes (active ingredient and jurisdiction).

2) Can you build a market and competition view for “LIDEX-E” from this prompt?
No, competition depends on indication, mechanism, and geography, none of which are provided.

3) Can you estimate launch timing and exclusivity strength for “LIDEX-E”?
No, launch timing and exclusivity require approval/filing status and patent expiry dates, which are not provided.

4) Can you provide an investment base case and risk range?
No, scenario modeling requires disease area, clinical phase, and legal timelines.

5) What is the minimum information needed to produce a complete analysis?
An active ingredient plus regulatory/clinical identifiers and the jurisdictions tied to patent and exclusivity analysis.

---

References

[1] None.